Using 18F-Fluciclovine PET/CT to Predict Outcomes of Prostate Cancer Therapy
Official title: Usefulness of Tumor Heterogeneity Assessment in Patients With MCRPC Undergoing Radioligand Therapy With 177LU-PSMA-617 Using Serial 18F-DCFPYL, 18F-FDG and 18F-Fluciclovine PET/CT Predicting Clinical Outcome
Run by VA Greater Los Angeles Healthcare System · NCT06706921 · Data updated 2026-11-12
This study is testing if special imaging can help predict how well a new prostate cancer treatment works for patients with advanced disease.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 15 (estimated) |
| Sponsor | VA Greater Los Angeles Healthcare System Federal |
| Locations | 1 site (Los Angeles, California) |
| Status | Recruiting |
| Started | December 15, 2024 |
| Main results expected | November 1, 2027 |
| Study ends | November 1, 2027 |
| Registry record updated | November 27, 2024 |
| Trial ID | NCT06706921 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adult males diagnosed with metastatic castration-resistant prostate cancer who are scheduled to receive LuPSMA RLT.
✕Probably not a fit
Patients under 18 years old or those with serious concurrent illnesses that may interfere with study procedures will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-center, prospective study focusing on patients with metastatic castration-resistant prostate cancer (mCRPC) who are scheduled to receive Lutetium labelled prostate-specific membrane antigen radioligand therapy (LuPSMA RLT). Participants will undergo baseline imaging with 18F-Fluciclovine PET/CT and will have follow-up scans after the 2nd, 4th, and 6th cycles of LuPSMA RLT. The study aims to analyze the imaging data to correlate PET metrics with clinical outcomes, providing insights into the effectiveness of the therapy. The goal is to assess how well these imaging techniques can predict patient responses to treatment.
Why it matters
Potential benefit: If successful, this study could enhance the ability to predict clinical outcomes for patients undergoing prostate cancer therapy, leading to more personalized treatment plans.
How similar studies have gone: Other studies have shown promise in using PET imaging to assess treatment responses in prostate cancer, suggesting that this approach may yield valuable insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with mCRPC scheduled to undergo LuPSMA RLT. * Willingness to undergo multiple serial PET/CT scans pre- and post-LuPSMA RLT. * Ability of providing written informed consent. Exclusion Criteria: * Less than 18 years-old at the time of radiopharmaceutical administration. * Medical condition, serious concurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study procedures or compliance. * Contraindications to LuPSMA RLT.
Where it's running
-
VA Greater Los Angeles Healthcare System
Los Angeles, California, United States Recruiting
Study contacts
- Study coordinator: Gholam Berenji, MD
- Email: Gholam.Berenji@va.gov
- Phone: 310-268-3547
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using vorolanib for treating advanced kidney cancer
This study is testing if the drug vorolanib can help people with advanced kidney cancer live longer when used as a second treatment option.
-
Combination of Gedatolisib and Darolutamide for Advanced Prostate Cancer
This study is testing a new combination of two drugs, gedatolisib and darolutamide, to see if they can help men with advanced prostate cancer feel better and improve their treatment outcomes.
-
Treatment with STAR0602 for advanced solid tumors
This study is testing a new treatment called STAR0602 to see if it can help people with advanced solid tumors by looking at how safe it is and how well it works.
-
Evaluating MRI and biopsy methods for prostate cancer detection
This study is testing whether a new type of MRI and a different way to do biopsies can help find prostate cancer more accurately in men who might have it.
-
Treatment for advanced prostate cancer using Lutetium-177
This study is testing a new treatment using Lutetium-177 for men with advanced prostate cancer that hasn't responded to other therapies to see how safe it is and how well it works.
-
Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer
This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.